Stocks Health care BBIO
NASDAQ · Health careBridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. brought in $945.5M of revenue over the twelve months to September 30, 2026, up 167.3% from a year earlier. It posted a net loss of $565.8M. In fiscal 2025 capital spending exceeded operating cash flow by $447M. At September 30, 2026 it held $1.5B in cash against $2.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about BridgeBio Pharma, Inc.
- Net worth
- BridgeBio Pharma, Inc. has a market value (market cap) of $15.4B at the latest share price, and shareholders' equity of -$1.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $502.1M (+126.3% year on year), with a net loss of $724.9M. Over the 12 months to September 30, 2026: revenue $945.5M, net loss $565.8M.
- Cash flow
- In fiscal 2025 operations used $445.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- BridgeBio Pharma, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What BridgeBio Pharma, Inc. does
BridgeBio Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $502.1M | -$724.9M | -$3.78 | -$447M |
| 2024 | $221.9M | -$535.8M | -$2.88 | -$521.7M |
| 2023 | $9.3M | -$643.2M | -$3.95 | -$529M |
| 2022 | $77.6M | -$481.2M | -$3.26 | -$424.3M |
| 2021 | $69.7M | -$562.5M | -$3.90 | -$511.2M |
| 2020 | $8.2M | -$448.7M | -$3.80 | -$407.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BBIO ranks in Health care
Dividends
It paid out $997K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2019 | n/a | $997K | n/a |
| 2017 | n/a | $1.2M | n/a |
Latest SEC filings
What BridgeBio Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 193% to $353.2M versus the same quarter last year; diluted EPS -$0.42 versus -$0.95.
- October 29, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 13, 2026Other event 8-K
- August 31, 2026Other event 8-K
- August 17, 2026Activist stake changed SCHEDULE 13D/A
- August 17, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 120% to $243.7M versus the same quarter last year; diluted EPS -$0.78 versus -$0.95.
- August 10, 2026
- August 3, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running BridgeBio Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Apuli MaricelChief Accounting Officer | Soldpre-planned (10b5-1) | 2,000 | $145.7K |
| September 17, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 8,721 | $601.9K |
| September 17, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 1,279 | $89K |
| August 19, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 8,100 | $679.3K |
| August 19, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 1,800 | $152.4K |
| August 19, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 100 | $8.6K |
| August 18, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,900 | $154.2K |
| August 18, 2026 | Kumar NeilChief Executive Officer, Director | Soldpre-planned (10b5-1) | 17,279 | $1.4M |
Who owns BBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| KKR Genetic Disorder L.P.13D, may seek influence with 8 related filers | 13.4% | September 17, 2024 |
| Janus Henderson Group PLC13G, passive | 6.8% | May 15, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 5.5% | August 3, 2026 |
| Dapice Joshua J.13G, passive with 27 related filers | 5.2% | May 29, 2026 |
| BlackRock, Inc.13G, passive | 5.1% | October 27, 2026 |
| Viking Global Investors LP13D, may seek influence with 6 related filers | 5% | July 10, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 474 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 14,110,278 | new |
| Kohlberg Kravis Roberts & Co. L.P. | 13,260,971 | 0 |
| Farallon Capital Management, L.L.C. | 10,743,063 | +1,377,600 |
| BlackRock, Inc. | 10,287,156 | -3,920,601 |
| Viking Global Investors LP | 9,949,219 | -1,893,215 |
| Vanguard Capital Management LLC | 7,898,973 | +139,478 |
| Vanguard Portfolio Management LLC | 7,656,722 | -423,851 |
| Wellington Management Group Llp | 5,308,924 | +2,824,971 |
| Two Sigma Investments, LP | 4,722,185 | +1,601,554 |
| Aisling Capital Management LP | 4,589,611 | -500,000 |
| State Street Corp | 4,435,932 | -498,388 |
| Citadel Advisors LLC | 3,760,028 | +586,088 |
| Invesco Ltd. | 3,700,934 | -891,880 |
| D. E. Shaw & Co., Inc. | 3,633,007 | +1,087,521 |
| Geode Capital Management, LLC | 3,418,419 | -1,499,611 |
| Jane Street Group, LLC | 2,934,193 | +1,176,521 |
| Jpmorgan Chase & Co | 2,397,995 | +1,085,736 |
| Adage Capital Partners GP, L.L.C. | 2,252,000 | +1,653,000 |
| Franklin Resources Inc | 2,160,173 | -278,752 |
| Polar Capital Holdings Plc | 2,063,609 | -455,697 |
Insiders
16 insiders reported holding 2,508,227 shares in total, about $197.3M at the last price.
| Holder | Shares |
|---|---|
| Homcy Charles JDirector | 919,876 |
| Kumar NeilChief Executive Officer, Director | 739,013495,686 held indirectly |
| Trimarchi ThomasPresident and CFO | 336,529 |
| Satvat Ali J.Director | 169,983 |
| Apuli MaricelChief Accounting Officer | 120,687 |
| Lo AndrewDirector | 68,66250,583 held indirectly |
| Hassan FredDirector | 29,879 |
| Ellis AndreaDirector | 22,579 |
| Daniels Ronald JDirector | 20,981 |
| Momtazee James CDirector | 19,070 |
Questions about BBIO
What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma, Inc. is a company in the Health care sector, listed on NASDAQ as BBIO. Its shares trade on NASDAQ under the ticker BBIO.
What is BridgeBio Pharma, Inc.'s net worth?
BridgeBio Pharma, Inc. has a market value (market cap) of $15.4B at the latest share price, and shareholders' equity of -$1.7B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BridgeBio Pharma, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $565.8M on revenue of $945.5M.
How much revenue does BridgeBio Pharma, Inc. make?
Over the twelve months to September 30, 2026 BridgeBio Pharma, Inc. reported revenue of $945.5M. That is 167.3% more than a year earlier.
When did BridgeBio Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 3, 2026.
When is BridgeBio Pharma, Inc.'s next earnings report?
BridgeBio Pharma, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BBIO with
Follow BBIO
Get an email when BridgeBio Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BridgeBio Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.